Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004
- PMID: 16956817
Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004
Abstract
Background and objectives: A large number of patients with thalassemia major have been born and treated exclusively in Cyprus. They have been managed according to standard international practice, but few have been transplanted. In 1999, a combination chelation regime with desferrioxamine and deferiprone was introduced. We analyzed survival trends in Cypriots and tried to identify factors associated with prolonged survival.
Design and methods: We had incomplete information on births pre-1974 and complete information from 1974 onwards. Clinical data were incomplete pre-1980 and complete thereafter. We analyzed data on 539 patients born after 1960 and followed over the period 1980 to the end of 2004.
Results: There were 58 deaths, 31 (53.4%) of which where due to cardiac causes. In the complete birth cohort of 284 patients born after 1974, survival (95% CI) at 10, 20 and 30 years was 100% (0); 98.5% (96.1-99.4) and 92.7% (86.7-96.1) respectively. There was a significant trend of increasing cardiac deaths between 1980 and 2000 (p<0.001) and a decline after 2000 (p=0.06). In multivariate survival analysis, protective effects were found for female sex (hazard ratio, 0.37, 95% CI 0.21-0.66; p<0.001), and post-2000 follow-up (hazard ratio, 0.44, 95% CI 0.20-0.99; p<0.05), but not for genotype, treatment center or birth cohort.
Interpretation and conclusions: Most patients born after 1974 survive to at least the age of 30. There has been a marked improvement in survival for patients of all ages since 2000, which may be due to the introduction of combination chelation therapy.
Comment in
-
Survival improvement in thalassemia: who should take the credit?Haematologica. 2006 Sep;91(9):1154B. Haematologica. 2006. PMID: 16956806 No abstract available.
-
Thalassemia. A few new tiles in a large mosaic.Haematologica. 2006 Sep;91(9):1159-61. Haematologica. 2006. PMID: 16956812 Review. No abstract available.
-
Cardiac determinants of survival in beta-thalassemia.Haematologica. 2006 Dec;91(12 Suppl):ELT11. Haematologica. 2006. PMID: 17194671 No abstract available.
Similar articles
-
Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.Haematologica. 2003 May;88(5):489-96. Haematologica. 2003. PMID: 12745268
-
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.Haematologica. 2004 Oct;89(10):1187-93. Haematologica. 2004. PMID: 15477202
-
Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.Hemoglobin. 2009;33(5):287-95. doi: 10.3109/03630260903212043. Hemoglobin. 2009. PMID: 19814674
-
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.Hemoglobin. 2008;32(1-2):1-15. doi: 10.1080/03630260701726533. Hemoglobin. 2008. PMID: 18274978 Review.
-
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.Transfusion. 2007 Oct;47(10):1919-29. doi: 10.1111/j.1537-2995.2007.01416.x. Transfusion. 2007. PMID: 17880620 Review.
Cited by
-
Prevalence of anemia and risk of adverse bleeding effect of drugs: implication for therapy.Anemia. 2012;2012:795439. doi: 10.1155/2012/795439. Epub 2012 Feb 28. Anemia. 2012. PMID: 22506109 Free PMC article.
-
Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.Haematologica. 2009 Dec;94(12):1777-8. doi: 10.3324/haematol.2009.009118. Epub 2009 Oct 8. Haematologica. 2009. PMID: 19815834 Free PMC article. No abstract available.
-
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.Cochrane Database Syst Rev. 2018 May 8;5(5):CD012349. doi: 10.1002/14651858.CD012349.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2023 Mar 6;3:CD012349. doi: 10.1002/14651858.CD012349.pub3. PMID: 29737522 Free PMC article. Updated. Review.
-
The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.Int J Mol Sci. 2024 Apr 25;25(9):4654. doi: 10.3390/ijms25094654. Int J Mol Sci. 2024. PMID: 38731873 Free PMC article. Review.
-
International survey of T2* cardiovascular magnetic resonance in β-thalassemia major.Haematologica. 2013 Sep;98(9):1368-74. doi: 10.3324/haematol.2013.083634. Epub 2013 Jun 28. Haematologica. 2013. PMID: 23812939 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical